Company news
Shandong Lukang Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Announcement on the Holding Subsidiary Obtaining the Supplementary Application Approval Notice for Methocarbamol Injection and Becoming the Marketing Authorization Holder of the Drug
August 29, 2025
Announcement on Canceling the Board of Supervisors and Amending the Articles of Association, and Revising, Formulating and Abolishing Some Goverance Systems
August 27, 2025
Announcement on SSE Approval of Application for Issuance of Shares to Specific Objects
August 20, 2025
Announcement on Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of CIGB-814 for Injection
August 19, 2025
Announcement on Cefuroxime Axetil for Suspension Passing Consistency Evaluation
August 13, 2025
Indicative Announcement on Reply Update to Letter of Review and Inquiry on Application Documents for Shares Issuance to Specific Objects
August 1, 2025
Semi-annual Earnings Preannouncement for 2025
July 14, 2025
Announcement on Obtaining Drug Registration Certificate and Approval Notice for Chemical Active Pharmaceutical Ingredient Market Application
July 8, 2025
Announcement on Reply to the Review Inquiry Letter of Application Documents for Issuance of Shares to Specific Objects by Shandong Lukang Pharmaceutical Co., Ltd. (Revised Draft)
July 7, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 20, 2025
Indicative Announcement on Replying to the Review Inquiry Letter of Application Documents for Issuing Shares to Specific Objects and Updates of Application Documents such as Prospectus
June 17, 2025
Announcement on Subsidiary's Drug Passing Generic Drug Consistency Evaluation
June 6, 2025
Announcement on the Progress of Receiving Land Collection and Storage Compensation for the Southern Factory Area
May 22, 2025
Reply to SSE Inquiry Letter on Ex Post Audit of the Company's 2024 Annual Report
May 14, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Shandong Jurisdiction
May 12, 2025
Announcement on Receiving Approval Notice of Marketing Application for Celecoxib as Chemical Active Pharmaceutical Ingredient
May 8, 2025
Announcement on Resolution of the 7th (Extraordinary) Meeting of the 11th Board of Directors
April 29, 2025
Announcement on Acceptance of Application for Issuance of A Shares to Specific Objects by Shanghai Stock Exchange
April 18, 2025
Announcement on Convening the 2024 Annual Performance Briefing
April 11, 2025
Announcement on Reception of Investor Research
April 2, 2025
Announcement on Renewing Engagement of Accounting Firm
March 21, 2025
Announcement on Obtaining Drug Registration Certificate by the Holding Subsidiary
February 10, 2025
Announcement on Expected Increase in Annual Performance for 2024
January 26, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025
January 16, 2025
Announcement on Abnormal Fluctuations in Stock Trading
January 13, 2025